Sol-Gel Technologies (SLGL) Receivables - Other (2022)

Sol-Gel Technologies' (SLGL) quarterly Receivables - Other came in at -$7.8 million in Q4 2022.

Sol-Gel Technologies (SLGL) Receivables - Other (2022) Analysis & Trends

Sol-Gel Technologies (SLGL) has 1 years of Receivables - Other data on file, last reported at -$7.8 million in Q4 2022.

On a quarterly basis, Receivables - Other changed N/A year-over-year to -$7.8 million in Q4 2022; TTM through Dec 2022 was -$7.8 million, a N/A change from a year earlier, with the FY2022 full-year figure at -$7.8 million, changed N/A from the prior year.
Receivables - Other for Q4 2022 stood at -$7.8 million.
Over the last five years, Receivables - Other for SLGL reached as high as -$7.8 million in Q4 2022 and fell as low as -$7.8 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Sol-Gel Technologies	227.58 Mn	217.44 Mn	-

Download Data

Date	Value
Dec 31, 2022	-7.80 Mn
Dec 31, 2022	-7.80 Mn